We use this value as the base for all calculations
Poster Session I - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P451 - ESOC25-1378 GENETIC INSIGHTS INTO PROTECTIVE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON STROKE AND ALZHEIMERS DISEASE RISK IN EUROPEAN AND EAST-ASIAN POPULATIONS Ilana Caro 1 , Muralidharan Sargurupremraj 2 , David-Alexandre Trgout 3 , Daichi Shigemizu 4,5 , Thierry Couffinhal 6,7 , Yoichiro Kamatani 8 , Kamel Mohammedi 6,9 , Stphanie Debette 3,10 1 Bordeaux Population Health research center, Inserm, UMR U1219, Universit de Bordeaux, Bordeaux, France, 2 Glenn Biggs Institute for Alzheimers and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, United States, 3 Bordeaux Population Health research center - Universit de Bordeaux, Bordeaux, France, 4 Medical Genome Center, National Center for Geriatrics and Gerontology, Aichi, Japan, 5 Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan, 6 Inserm, Biologie Des Maladies Cardiovasculaires, U1034, Universit de Bordeaux, Bordeaux, France, 7 Department of Cardiology, CHU de Bordeaux, Bordeaux, Bordeaux, France, 8 Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan, 9 Department of Endocrinology, Diabetology and Nutrition, CHU de Bordeaux, Bordeaux, France, 10 Department of Neurology, Institute for Neurodegenerative Diseases, CMRR, CHU de Bordeaux, Bordeaux, France Background and Aims: Stroke and dementia are leading causes of death and disability worldwide requiring enhanced preventive strategies
An ideal antioxidant is expected to mitigate excess oxidative stress, but not to disturb redox homeostasis
Statements Author contributions AS: Conceptualization, Methodology, Resources, Writing original draft, Writing review & editing
